External validity of randomized controlled trials of glycaemic control and vascular disease: How representative are participants?

Diabetic Medicine

Volumn 30, Issue 3, 2013, Pages 300-308

  Saunders, C ^a   Byrne, C D ^b   Guthrie, B ^c   Lindsay, R S ^d   Mcknight, J A ^e   Philip, S ^f   Sattar, N ^d   Walker, J J ^a   Wild, S H ^a   Brady, I ^a   Chalmers, J ^a   Colhoun, H ^a   Cunningham, S ^a   Elder, R ^a   Emslie Smith, A ^a   Fischbacher, C ^a   Govan, L ^a   Jones, N ^a   Lese, G ^a   Levine, D ^a   Livingstone, S ^a   Looker, H ^a   McAlpine, R ^a   Morris, A ^a   Pearson, D ^a   Petrie, J ^a   more..

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EXTERNAL VALIDITY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH SUBJECTS; SCOTLAND;

EID: 84874174557     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12047     Document Type: Article

References (29)

1. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162: 1682-1688.
2. Hutchins LF, Unger JM, Crowley J, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
3. Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol 1996; 27: 1335-1342.
4. Ramasubbu K, Gurm H, Litaker D. Gender bias in clinical trials: do double standards still apply? J Womens Health Gend Based Med 2001; 10: 757-764.
5. Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. J Am Med Assoc 2007; 297: 1233-1240.
6. Masoudi FA, Havranek EP, Wolfe P, Rathore SS, Steiner JF, Ordin DL et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003; 146: 250-257.
7. Fox C, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RK et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115: 1544-1550.
8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
9. McKnight JA, Morris AD, Cline D, Peden N, Fischbacher C, Wild S et al. Implementing a national quality assurance system for diabetes care: the Scottish Diabetes Survey 2001-2006. Diabet Med 2008; 25: 743-746.
10. Walker JJ, Livingstone SJ, Colhoun HM, Lindsay RS, McKnight JA, Morris AD et al. Effect of socioeconomic on mortality among people with type 2 diabetes: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care 2001; 34: 1127-1132.
11. Collaborators on Trials of Lowering Glucose (CONTROL) Writing Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
12. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011; 54: 25-31.
13. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
14. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
15. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
16. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
17. UK Prospective Diabetes Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998; 352: 837-853.
18. UK Prospective Diabetes Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. UKPDS 34. Lancet 1998; 352: 854-865.
19. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
20. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51: 1127-1134.
21. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group. Improvements of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
22. Yudkin JS, Richter B. Intensive glucose control and cardiovascular outcomes. Lancet 2009; 374: 522.
23. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. J Am Med Assoc 2006; 296: 1377-1384.
24. Food and Drug Administration (Centre for Drug Evaluation and Research). Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Last accessed 4 February 2012.
25. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359: 1092-1095.
26. Preiss D, Sattar N, McMurray JJ. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J 2011; 161: 210-219.
27. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007; 62: 219-223.
28. Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall M et al. External validity of randomised controlled trials in COPD. Respir Med 2007; 101: 1313-1320.
29. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.